


Tissue Iron Deposition: MRI Quantitation in Clinical Trials

By Benjamin Tubb, M.D., Diagnostic Radiology · Updated for 2026 by Intrinsic Imaging



Iron overload is the inevitable consequence of chronic transfusion and of ineffective erythropoiesis in thalassemia, sickle cell disease and myelodysplastic syndromes. Each unit of blood delivers about 200 mg of iron the body cannot excrete, and the resulting deposition in liver, heart and endocrine organs was for decades the leading cause of death in transfusion-dependent thalassemia. MRI changed that. Non-invasive measurement of liver iron concentration and cardiac T2* replaced biopsy, revealed cardiac iron that serum ferritin could not predict and gave chelation trials objective endpoints. With gene therapies and new disease-modifying drugs now approved, quantitative iron MRI is more important than ever. This issue explains the methods and what sponsors should specify.

Why Ferritin and Biopsy Were Not Enough

Serum ferritin is inexpensive and widely used but is an acute-phase reactant that rises with inflammation and infection, and it correlates poorly with cardiac iron. Liver biopsy measures iron directly but is invasive, prone to sampling error from heterogeneous deposition and fibrosis, and unsuitable for repeated measurement in a trial. Neither method could identify the patients whose hearts were loading iron while their ferritin and liver values looked acceptable.

MRI exploits the fact that iron is paramagnetic. Tissue iron shortens the transverse relaxation times T2 and T2*, and the corresponding relaxation rates R2 (1/T2) and R2* (1/T2*) increase in proportion to iron concentration. Measuring those rates provides a quantitative, reproducible and non-invasive estimate of tissue iron.

Liver Iron Concentration

Two MRI methods have been calibrated against biopsy. The spin-echo R2 method, commercialized as FerriScan, was validated against biopsy liver iron concentration and cleared by the FDA in 2005; it requires centralized analysis and is the method most often used in chelator registration trials. The gradient-echo R2* method is faster, acquired in a single breath-hold, and was calibrated against biopsy by Wood and colleagues in 2005, with subsequent work es-

tablating that R2* calibration is consistent across scanners and field strengths when acquisition parameters are controlled.^{1,2} Recent validation studies confirm close agreement between R2* and R2-based LIC when standardized protocols are used.³

Clinically, LIC below 3 mg Fe/g dry weight is normal or near-normal, 7 mg/g marks the threshold above which complications accelerate, and values above 15 mg/g carry a high risk of cardiac disease and death. Trials typically report change in LIC at 6, 12 or 24 months as a primary or key secondary endpoint for chelation and for therapies that reduce transfusion burden.

Cardiac T2*: The Measurement That Changed Outcomes

Anderson and colleagues showed in 2001 that a multi-echo gradient-echo measurement of myocardial T2* in the interventricular septum identifies cardiac iron loading and that T2* below 20 ms indicates iron overload.⁴ A subsequent prospective study of more than 650 patients demonstrated that T2* below 10 ms predicts a very high risk of heart failure within one year, which made cardiac T2* the trigger for intensified chelation.⁵ Myocardial T2* was then directly calibrated against iron concentration in post-mortem hearts, confirming the relationship.⁶ The in-

roduction of cardiac T2* screening is credited with a dramatic fall in cardiac mortality in thalassemia major.

International guidelines from the Thalassaemia International Federation recommend annual cardiac T2* and LIC assessment in transfusion-dependent patients, with more frequent imaging in those with T2* below 20 ms.⁷ The same thresholds and schedules are used in trials to define eligibility, stratify risk and measure response.

New Therapies Raise the Stakes

The therapeutic landscape has changed quickly. Luspatercept, approved in 2019, reduces transfusion burden in beta-thalassemia; in its pivotal trial, significantly more treated patients than controls achieved at least a one-third reduction in transfusions.⁸ Betibeglogene autotemcel, a lentiviral gene therapy, was approved in August 2022, and exagamglogene autotemcel, the first CRISPR-based therapy, in January 2024 for transfusion-dependent thalassemia; both aim at transfusion independence.^{9,10} Mitapivat, an oral pyruvate kinase activator, was approved on December 23, 2025 for anemia in adults with alpha- or beta-thalassemia.¹¹ Each of these programs needs to show what happens to tissue iron when transfusions stop or fall: iron does not leave the body on its own, so LIC and cardiac T2* trends after treatment are critical secondary endpoints and long-term safety measures.

Technical Requirements for Trials

Iron MRI is quantitative only if acquisition is controlled. Protocols must fix field strength, echo times, flip angle and slice position; must avoid parallel imaging and fat-suppression settings that alter signal decay; and must specify the fitting model, including how to handle the signal plateau at very high iron where R2* exceeds measurable range at 3T. Phantom calibration across sites, central analysis by a single laboratory and documented reader re-

producibility are expected by regulators for a primary imaging endpoint.¹²

Guidance for Sponsors

Imaging iron in a hematology trial

- **Pick the LIC method and stick to it.** R2 or R2*, with a single calibration applied for the entire trial.^{1,2}
- **Always include cardiac T2*.** Ferritin and LIC do not predict cardiac iron; T2* under 20 ms defines overload and under 10 ms high risk.^{4,5}
- **Specify the acquisition.** Field strength, echo train, flip angle, breath-hold and slice position fixed in the imaging charter.
- **Qualify sites with phantoms.** Confirm cross-site agreement before enrollment and after scanner upgrades.
- **Plan for post-transfusion-independence follow-up.** Gene and disease-modifying therapies need long-term iron trends.^{9,10,11}
- **Analyze centrally.** One core lab, one fitting model, blinded readers.¹²

Summary

Quantitative iron MRI turned a lethal, invisible complication into a measurable and treatable one, and in doing so changed the survival of a generation of patients with thalassemia. For sponsors of chelators, disease-modifying agents and gene therapies alike, the message is the same: standardize acquisition, calibrate across sites and read centrally so that every milligram of iron measured means the same thing everywhere.

About the Author

Dr. Benjamin Tubb, a radiologist at Intrinsic Imaging, wrote the original edition of this issue. He completed his residency in diagnostic radiology and fellowship training in body imaging, and he interprets quantitative abdominal and cardiac MRI for hematology, hepatology and oncology trials. He is board-certified in diagnostic radiology.

References

1. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. *Blood*. 2005;106(4):1460–1465. doi.org/10.1182/blood-2004-10-3982
2. Garbowski MW, Carpenter JP, Smith G, et al. Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. *J Cardiovasc Magn Reson*. 2014;16:40. doi.org/10.1186/1532-429X-16-40
3. Validation of R2* magnetic resonance imaging for quantifying liver and cardiac iron compared with the R2-based method. *Diagn Interv Radiol*. 2025;31(5):399–404. dirjournal.org
4. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. *Eur Heart J*. 2001;22(23):2171–2179. doi.org/10.1053/euhj.2001.2822
5. Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. *Circulation*. 2009;120(20):1961–1968. doi.org/10.1161/CIRCULATIONAHA.109.874487
6. Carpenter JP, He T, Kirk P, et al. On T2* magnetic resonance and cardiac iron. *Circulation*. 2011;123(14):1519–1528. doi.org/10.1161/CIRCULATIONAHA.110.007641
7. Farmakis D, Porter J, Taher A, et al. 2021 Thalassaemia International Federation guidelines for the management of transfusion-dependent thalassemia. *HemaSphere*. 2022;6(8):e732. onlinelibrary.wiley.com
8. Cappellini MD, Viprakasit V, Taher AT, et al. A phase 3 trial of luspatercept in patients with transfusion-dependent beta-thalassemia. *N Engl J Med*. 2020;382(13):1219–1231. doi.org/10.1056/NEJMoa1910182
9. U.S. FDA. ZYNTEGLO (betibeglogene autotemcel): approval information. August 17, 2022. fda.gov
10. U.S. FDA. CASGEVY (exagamglogene autotemcel): approval information. January 16, 2024. fda.gov
11. Agios Pharmaceuticals. U.S. FDA approves Aqvesme (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia. December 2025. investor.agios.com
12. U.S. FDA. Clinical trial imaging endpoint process standards: guidance for industry. April 2018. fda.gov

About Intrinsic Imaging, LLC

Headquartered in Bolton, Massachusetts, Intrinsic Imaging is an imaging CRO and core lab supporting Phase I–IV drug trials, medical device studies and AI/CAD validation studies. The company has completed three FDA Bioresearch Monitoring Program inspections, each with zero Form FDA 483 observations, and holds five BSI certifications: ISO 9001, ISO 13485, ISO 22301, ISO/IEC 27001 and ISO/IEC 27018. Its network of more than 1,000 board-certified, fellowship-trained physicians has supported trials at more than 4,000 sites in 64 countries.



Contact

Intrinsic Imaging, LLC
 580 Main Street, Suite 210
 Bolton, MA 01740
 Tel: +1 978-616-4650
 Contact@IntrinsicImaging.com
 www.IntrinsicImaging.com